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Abstract
Background: Accurate T-staging is pivotal for predicting prognosis and selecting appropriate therapies for
esophageal squamous cell carcinoma (ESCC). The diagnostic performance of fluorodeoxyglucose (FDG) positron
emission tomography/computed tomography (PET/CT) for its T-staging is uncertain. We investigated use of FDG
PET/CT for preoperative T-staging of patients with ESCC.
Methods: Patients with ESCC given preoperative FDG PET/CT scans, either with (CRT[+] group) or without (CRT[−]
group) neoadjuvant chemoradiotherapy, were retrospectively reviewed. Maximal standardized uptake value
(SUVmax) of the primary tumors on FDG PET/CT scans were measured, and histopathological results were used as
the reference standard. The associations between pathological T-stage and potential factors of age, tumor location,
tumor grade, tumor size, and tumor SUVmax were analyzed. The cut-off levels of SUVmax for predicting different
T-stages and for residual viable tumors after neoadjuvant chemoradiotherapy were determined using receiver
operating characteristic analyses.
Results: We enrolled 103 patients (45 in the CRT[−] group; 58 in the CRT[+] group). SUVmax, an independent predictive
factor, positively correlated with the pathological T-stage in both groups (CRT[−] group: ρ = 0.736, p < 0.001; and CRT[+]
group: ρ = 0.792, p < 0.001). The overall accuracy of the PET/CT with thresholded SUVmax for predicting the pathological
T-stage was 73.3% in the CRT[−] group (SUVmax of T0: 0–1.9, T1: 2.0–4.4, T2: 4.5–6.5, T3: 6.6–13.0, T4: >13.0) and 67.2% in
the CRT[+] group (SUVmax of T0: 0–3.4, T1: 3.5–3.9, T2: 4.0–5.5, T3: 5.6–6.2, T4: > 6.2). For CRT
[−] group, the accuracy using
an SUVmax cut-off of 4.4 to differentiate early (T0-1) from locally advanced disease (T2-4) was 82.2% (95% CI, 71.1–93.
4%). For CRT[+] group, the accuracy using an SUVmax cut-off of 3.4 to predict residual viable tumors (non-T0) after
completion of chemoradiotherapy was 82.8% (95% CI, 73.0–92.5%).
Conclusions: The FDG avidity of a primary esophageal tumor significantly positively correlated with the pathological
T-stage. PET/CT with thresholded SUVmax was useful for predicting T-stage and differentiating residual viable tumors.
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Background
Esophageal cancer, a poor prognostic disease with an esti-
mated 5-year survival of 17–34%, occurs worldwide and is
a leading cause of cancer mortality [1–3]. The two major
histological types of esophageal cancer are squamous cell
carcinoma and adenocarcinoma, which have different
tumor biology and treatment outcomes [4]. With more
sensitive to chemoradiation, esophageal squamous cell
carcinoma (ESCC) has a higher complete response rate
after neoadjuvant chemoradiotherapy (CRT) than adeno-
carcinoma [5]. In patients with resectable locally advanced
ESCC, recent phase III study and meta-analysis have
shown that neoadjuvant CRT followed by surgery is super-
ior to surgery alone [6, 7]. After definitive CRT, around
32–46% of patients were free of viable tumors on the final
surgical pathology examination [8, 9]. If tumors are totally
eradicated after CRT, salvage esophagectomy predisposing
to additional postoperative mortality (rate up to 10%) and
morbidity (rate up to 50%) [10–12] may be unnecessary.
Otherwise, surgery is suggested to eliminate local residual
disease. To determine the most suitable therapy and to
avoid inappropriate attempts at curative surgery, accurate
preoperative T-stage and assessment of a patient’s re-
sponse to CRT are required.
Endoscopic ultrasound (EUS) is considered the most
accurate procedure for preoperative local staging of
ESCC, but it is unreliable for staging after CRT largely
due to the therapeutic related inflammatory effect or
fibrosis [13, 14]. Moreover, EUS is relatively invasive and
operator-dependent and it has two other limitations: se-
vere stenosis blocks the passage of the endoscope, and its
finite depth of penetration may be insufficient for staging
T4 tumors.
For the initial staging and for evaluating a patient
after CRT, the fluorodeoxyglucose (FDG) positron
emission tomography/computed tomography (PET/CT)
is useful for detecting lymphatic and hematogenous
metastasis before surgery [15, 16]. But because of the
limited spatial resolution, its role in classifying the T-
stage is uncertain. For ESCC, there have been no estab-
lished findings about the diagnostic ability of FDG
PET/CT to predict the pathological T-stage. FDG avid-
ity, semiquantitatively measured using standardized
uptake values (SUVs) that reflect the aggressiveness of
the neoplasm, can predict the extent of esophageal can-
cer [17, 18]. Some studies [18–20] have found associa-
tions between FDG avidity and T-stage, but the results
are inconsistent, especially after neoadjuvant CRT. The
routine use of FDG PET/CT for ESCC continues to
grow. Beyond its well-known value in determining N
and M stages, it is worth exploring its diagnostic per-
formance for the T-stage. We investigated the applica-
tion of FDG PET/CT for the preoperative T-staging of
ESCC with and without neoadjuvant CRT.
Methods
Study design
We retrospectively reviewed consecutive ESCC patients
who had undergone preoperative FDG PET/CT scans be-
fore the resection of their esophageal tumors in Chang
Gung Memorial Hospital, Kaohsiung, Taiwan, between
2007 and 2013. Eligible patients were categorized into the
CRT[−] group, who did not undergo CRT for ESCC before
resection, and the CRT[+] group, who did and had FDG
PET/CT after CRT. The CRT consisted of two cycles of 5-
fluorouracil/cisplatin-based chemotherapy and thoracic
radiation (3600 ~ 5040 cGy). All patients who underwent
surgery had a radical esophagectomy with a cervical eso-
phagogastrostomy or an Ivor Lewis esophagectomy with
intrathoracic anastomosis, a two-field lymphadenectomy,
reconstruction of the digestive tract with a gastric tube
and pylorus drainage procedures. We used histopatho-
logical results as the reference standard. The pathological
T-stages (T1-T4) were classified according to the 7th
American Joint Committee on Cancer staging system [21].
For statistical analysis, high grade dysplasia (Tis) was
classified as T0. The resected tissue was labeled by the
surgeon and sent for pathological examination. The
histopathological assessment was independently carried
out by two pathologists, and a consensus was reached.
For CRT[+] group, pathologically complete response of
primary tumor (T0) was defined as the complete dis-
appearance of viable cancer cells in the tumor surgical
specimens. Tumor histological grade (Gr1-Gr3) and
tumor size (greatest dimension in cm) of the specimen
as well as the initial biopsy location as proven ESCC via
endoscopy were also recorded. We measured the maximal
standardized uptake values (SUVmax) of the primary
esophageal tumors on FDG PET/CT scans. Multivariate
analyses were used to evaluate the associations between
pathological T-stage and the potential factors of age,
tumor location, tumor grade, tumor size, and tumor
SUVmax. The cut-off levels of SUVmax for predicting
different T-stages and for residual viable tumors after
neoadjuvant CRT were determined using receiver op-
erating characteristic (ROC) analyses. This retrospect-
ive study was approved by the Institutional Review
Board of the Chang Gung Memorial Hospital with a
waiver of consent.
FDG PET/CT
After the patients had fasted for at least 6 h, they were
injected with 370–555 MBq of FDG. PET/CT scans were
initiated 1 h later using a combined PET/CT scanner
(Discovery ST; GE Healthcare, Waukesha, WI, USA). For
attenuation correction and imaging fusion, nonenhanced
CT scans were acquired first from the mid-thigh to the
head using the following parameters: 140 kV, 170 mA
(maximum), and 3.75-mm thick sections. PET scans were
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then taken over the same anatomical regions for 5 min
per bed position. The transaxial PET images were
reconstructed using an ordered subsets expectation
maximization algorithm in a matrix of 128 × 128-pixel
with a slice thickness of 3.27 mm. The reconstructed
images displayed in coronal and sagittal planes as well
as maximum intensity projection images were also
available for interpretation. SUVs were calculated ac-
cording to the formula: SUV =measured activity within
the region of interest (MBq/mL)/[injected dose of FDG
(MBq)/body weight (g)]. The PET/CT images were
reviewed and analyzed by a nuclear medicine physician
(YCH, 7 years of experience in PET/CT reporting).
Discrepancies with the routine PET/CT reports were
resolved by consensus reviewing with a second nuclear
medicine physician (CCH, 8 years of experience in PET/
CT reading).
Statistical analyses
Continuous variables were expressed as means with
standard deviations (SD). Kolmogorov-Smirnov statistics
were used to test the data sets for normal distribution.
Student’s t-test was used in group comparisons of nor-
mally distributed data, and the Mann–Whitney U-test
was used for data that were not normally distributed.
Categorical variables were analyzed using the χ2 test.
Potential factors associated with the pathological T-stage
were identified separately in the CRT[−] and the CRT[+]
group patients using ordinal logistic regression for
multivariate analyses. The SUVmax of esophageal tumors
in the 5 different pathological T-stages were compared
using Kruskal-Wallis tests, and then analyzed using the
Jonckheere-Terpstra test for ordered alternatives. The
correlations between the SUVmax of esophageal tumors
and pathological T-stages were analyzed using Spear-
man rank correlations. The cut-off levels of SUVmax for
predicting different T-stages and for residual viable
tumors in the CRT[+] group were investigated using
ROC analyses. The agreements between threshold-
SUVmax and pathological T-stage were assessed from 5 × 5
tables using κ statistics. The κ values were classified as fol-
lows: ≤ 0.2, poor agreement; 0.21–0.4, fair agreement;
0.41–0.60, moderate agreement; 0.61–0.8, good agree-
ment; and 0.81–1, excellent agreement. The sensitivity,
specificity, positive predictive value (PPV), negative pre-
dictive value (NPV), and accuracy were calculated using
standard formulas. SPSS 17 for Windows (SPSS Inc.,
Chicago, IL, USA) was used for all statistical analysis.
Significance was set at p < 0.05.
Results
Of the 839 patients with ESCC that we reviewed, 103
eligible patients (100 men, 3 women; mean age: 53.6 ±
8.2 years old) were included in the analysis. The study
flow chart with inclusion and exclusion criteria summa-
rizes how the eligible patients were collected (Fig. 1).
Forty-five patients had not undergone neoadjuvant CRT
(the CRT[−] group) and 58 patients had (the CRT[+]
group). The demographic features of the patients are sum-
marized in Table 1. All of them had completed the FDG
PET/CT scan. Their fasting blood sugar at scans was
102.2 ± 19.5 mg/dl (range: 61–175 mg/dl, CRT[−] group:
96.6 ± 18.9 mg/dl; CRT[+] group: 106.5 ± 19.0 mg/dl).
Time from FDG injection to PET/CT scans was 61.7 ±
8.5 min (CRT[−] group: 60.8 ± 7.6 min; CRT[+] group: 62.4
± 9.1 min). The FDG PET/CT scans did not identify the
Fig. 1 Flowchart of patients’ assessment for eligibility in the study
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primary lesion in 2 of 2 patients with Tis lesions and 3 of
26 patients with T1 lesions in the CRT[−] group or in the 1
patient with a Tis lesion and 2 of 4 patients with T1
lesions in the CRT[+] group; they did, however, detect all
the other primary tumors.
The multivariate ordinal logistic regression analysis
showed that both the SUVmax and tumor size were inde-
pendent predictive factors of the pathological T-stage in
the CRT[−] group, but that the SUVmax was the only in-
dependent predictive factor of the pathological T-stage
in the CRT[+] group (Table 2).
The SUVmax between the five stages were significantly
different between groups (Kruskal-Wallis Test; all p <
0.001), and a higher SUVmax was associated with a higher
pathological T-stage (Jonckheere-Terpstra Trend Test
across the 5 stages; all p < 0.001). There were positive cor-
relations between the tumor SUVmax and the pathological
T-stage (CRT[−] group: ρ = 0.736, p < 0.001; and CRT[+]
group: ρ = 0.792, p < 0.001) (Fig. 2).
ROC curves for SUVmax were plotted to compare T0
vs. T1–4, T0–1 vs. T2–4, T0–2 vs. T3–4, and T0–3 vs.
T4. According to the ROC curves, the ranges of SUVmax
cut-offs selected were: for the CRT[−] group = T0: 0–1.9,
T1: 2.0–4.4, T2: 4.5–6.5, T3: 6.6–13.0, T4: >13.0; and for
the CRT[+] group = T0: 0–3.4, T1: 3.5–3.9, T2: 4.0–5.5,
T3: 5.6–6.2, T4: > 6.2 (Table 3). For CRT[−] group, the
accuracy of differentiating early (T0–1) from locally ad-
vanced disease (T2–4) was 82.2% (95% CI, 71.1–93.4%).
Representative cases of the FDG uptake in pathological
T1–T4 esophageal tumors are shown in Fig. 3. Using
PET/CT with thresholded SUVmax, the T-stage was over-
staged for 9 of the patients (20.0%) and understaged for
3 (6.7%) in the CRT[−] group; and it was overstaged for 8
of the patients (13.8%) and understaged for 11 (19.0%) in
the CRT[+] group. The overall accuracy of the thresholded
SUVmax for predicting pathological T-stage were 73.3%
(κ = 0.628, good agreement) in the CRT[−] group and
67.2% (κ = 0.538, moderate agreement) in the CRT[+]
group (Table 4).
To detect residual viable tumor (non-T0) after CRT,
the optimal SUVmax cut-off was 3.4 with sensitivity of
81.3% (95% CI, 63.0–92.1%); specificity of 84.6% (95%
CI, 64.3–95.0%); PPV of 86.7% (95% CI, 68.4-95.6%);
NPV of 78.6% (95% CI, 58.5–90.1%); and accuracy of
82.8% (95% CI, 73.0–92.5%). The area under the ROC
curve was 0.89 (95% CI, 0.77–0.95, p < 0.001). Setting
the SUVmax cut-off value at 2.2 with a negative likeli-
hood ratio of 0.07 reduced the false-negative rate to
3.1% (sensitivity: 96.9%, specificity: 46.2%). Setting it at
5.5 with a positive likelihood ratio of 13.00 reduced the
false-positive rate to 3.9% (sensitivity: 50%, specificity:
96.1%).
Table 1 Demographic and clinical characteristics of patients
Characteristic Total (n = 103) CRT[−] group (n = 45) CRT[+] group (n = 58)
Age, years 53.6 (8.2)a 54.4 (8.0)a 53.1 (8.4)a
Gender (male:female) 100:3 (97%:3%) 44:1 (98%:2%) 56:2 (97%:3%)
Tumor location (upper:middle:lower) 25:52:26 (24%:51%:25%) 9:21:15 (20%:47%:33%) 16:31:11 (28%:53%:19%)
T-stage (T0:T1:T2:T3:T4) 28:30:14:20:11 (27%:29%:14%:19%:11%) 2:26:7:9:1 (4%:58%:16%:20%:2%) 26:4:7:11:10 (45%:7%:12%:19%:17%)
Tumor gradeb (G1:G2:G3) 4:60:11b (5%:80%:15%) 2:36:5b (5%:84%:11%) 2:24:6b (6%:75%:19%)
Tumor size, cm 2.7 (1.4)a 2.7 (1.3)a 2.7 (1.5)a
Tumor SUVmax 5.0 (3.0)
a 5.3 (2.9)a 4.7 (3.0)a
CRT to PET/CT interval, days N/A N/A 52.2 (48.5)a
PET/CT to resection interval, days 24.4 (20.1)a 21.2 (20.9)a 26.8 (19.4)a
aData are means (standard deviation)
bTumor histological grade was not assessment in patients with resected tumor specimens classified as T0
CRT chemoradiotherapy, PET/CT positron emission tomography/computed tomography, SUVmax maximal standardized uptake value
Table 2 Multivariate analysis of the pathological T-stage
Parameter Coefficient 95% confidence interval p Value
CRT[−]group
Age 0.066 −0.047 ~ 0.179 0.253
Tumor locationa 0.748 −1.114 ~ 2.611 0.431
Tumor gradeb 2.139 −1.393 ~ 5.671 0.235
Tumor size 0.715 0.038 ~ 1.392 0.038*
Tumor SUVmax 0.894 0.400 ~ 1.389 <0.001*
CRT[+]group
Age −0.027 −0.108 ~ 0.053 0.504
Tumor locationa 0.756 −0.955 ~ 2.468 0.386
Tumor gradeb −1.661 −3.814 ~ 0.493 0.131
Tumor size 0.206 −0.425 ~ 0.837 0.523
Tumor SUVmax 1.111 0.530 ~ 1.692 <0.001*
aLower vs. Upper + Middle
bGrade 3 vs. Grade 1 + 2. Tumor histological grade was not assessment in
patients with resected tumor specimens classified as T0
*Statistically significant
CRT chemoradiotherapy, SUVmax maximal standardized uptake value
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Discussion
Our study showed that SUVmax of the esophageal tumor
was the most significant independent factor associated
with the pathological T-stage. Furthermore, using ROC
analysis to define SUVmax cut-offs, we found that FDG
PET/CT was able to predict pathological T-stage with
acceptable accuracy (CRT[−] group: 73.3%; CRT[+] group:
67.2%). Using an SUVmax cut-off of 4.4 to differentiate
early (T0-1) from locally advanced disease (T2–4) for
CRT[−] group and an SUVmax cut-off of 3.4 to predict
residual viable tumors (non-T0) for CRT[+] group,
yielded an optimal diagnostic accuracy of 82.2% and
82.8%, respectively. These results indicated FDG PET/
CT may provide preoperative T-staging of ESCC.
The SUVmax is a widely accepted and feasible param-
eter of PET/CT image used for cancer diagnosis and
disease evaluation [17, 20, 22–25] because it is less ob-
server-dependent and more reproducible than SUVmean
[26]. There must be variation in SUVmax used among
different institutions with different PET/CT equipment.
Our data were derived from the same PET/CT scanner
with standardized image acquisition and reconstruction
protocol that minimized the variation of technological
factors. The other biological factors including radio-
tracer distribution time and level of fasting blood glu-
cose were within a limited range, which would reduce
variability in our SUV data. Another parameter of FDG
PET, the total lesion glycolysis (TLG), is defined as the
product of SUVmean and metabolic tumor volume
(MTV). The TLG values are believed to reflect both the
biological aggressiveness and tumor burden. Although
data are limited with respect to TLG and esophageal
cancer, recent reports suggest that TLG may be a useful
prognostic factor [27, 28]. However, the lesions are usually
defined by using a threshold method and thus the setting
of threshold will result in some degree of variations in
SUVmean, MTV and TLG. Currently, no single optimal
threshold can provide accurate tumor delineation. Further
validation of different published methods for measuring
the tumor volumes is still needed.
PET/CT is known to have a limited role in evaluating
an early-stage cancer with small volume and its T descrip-
tor because of its restrictive spatial resolution. Using CT
anatomical information and knowledge of the distance
Fig. 2 The relationships between the SUVmax of esophageal tumors and pathological T-stages. a Means of esophageal tumor SUVmax for the five
pathological T-stages in the CRT[−] group (blue bars) and the CRT[+] group (red bars). A higher SUVmax was associated with a higher pathological
T-stage (Jonckheere-Terpstra Trend Test across the 5 stage, all p < 0.001). Error bars were standard deviations. b The SUVmax of esophageal tumors
were plotted against pathological T-stages in the CRT[−] group (blue dots) and the CRT[+] group (red dots). There were positive correlations between the
tumor SUVmax and pathological T-stage (all p < 0.001)
Table 3 Determination of SUVmax cut-offs for pathological T-stage
T-stage SUVmax cut-off AUROC curve 95% confidence interval
CRT[−]group
T≥ T1 1.9 1.00a 0.92 ~ 1.00
T≥ T2 4.4 0.88a 0.75 ~ 0.96
T≥ T3 6.5 0.95a 0.84 ~ 0.99
T : T4 13.0 N/Ab N/A
CRT[+]group
T≥ T1 3.4 0.89a 0.77 ~ 0.95
T≥ T2 3.9 0.93a 0.83 ~ 0.98
T≥ T3 5.5 0.95a 0.85 ~ 0.99
T : T4 6.2 0.95a 0.86 ~ 0.99
ap < 0.05
bData unavailable because there was only one patient with a T4 tumor in the
CRT[−] group
AUROC area under the receiver-operating-characteristic, CRT chemoradiotherapy,
SUVmax maximal standardized uptake value
Huang et al. BMC Medical Imaging  (2017) 17:1 Page 5 of 8
from the incisors to the tumor being endoscopically
viewed, we could identify the ESCC for 25 of 30 patients
(83.3%) with T1 tumors on PET/CT scans, even though it
could not identify Tis tumors. The detection rate was
much higher than that obtained using a PET scanner
alone, which ranged from 43 to 55% [29, 30], and slightly
higher than the 71% for T1 tumors reported by Manabe et
al. [20], who used a PET/CT scanner.
Sun et al. [31] reported that tumor length affects FDG
uptake in esophageal cancer, and that the T-stage of the
primary tumor is not significantly correlated with the
SUVmax after controlling for length. However, instead of
multiplying the number of slices by the slice thickness
on PET scans for tumor length and using clinical T-
stage for the reference standards as they did, we used
the pathological tumor size and pathological T-stage of
the specimens as reference standards to permit a more
reliable evaluation.
In the CRT[−] group, the major mistake made by PET/
CT with thresholded SUVmax was overstaging, which
accounted for 75% (9/12) of the erroneously staged pa-
tients. Six of the nine overstaged patients had polypoid
tumors. A polypoid tumor protruding into the esopha-
geal lumen but not aggressively extended through the
esophageal wall might show high FDG avidity without
being at an advanced T-stage. A representative example
is shown in the additional file (Additional file 1: Figure
S1). Using thresholded SUVmax to predict pathological
T-stage, we need to be aware of the pitfall that polypoid
tumors might have high SUVmax and thus can be easily
Fig. 3 FDG PET (a–d) and corresponding fused PET/CT (e–h) transaxial images of four representative patients in the CRT[−] group. Increased FDG
uptake ranged from mild to intense in the pathologically proven T1 tumor with SUVmax = 3.5 (a, e); T2 tumor with SUVmax = 5.8 (b, f); T3 tumor
with SUVmax = 8.2 (c, g); T4 tumor with SUVmax = 13.7 (d, h). The reference ranges of SUVmax cut-offs selected for CRT
[−] group were T1: 2.0–4.4, T2:
4.5–6.5, T3: 6.6–13.0, T4: >13.0
Table 4 Diagnostic performance of PET/CT using thresholded
SUVmax
Pathological T-stage
T0 T1 T2 T3 T4




T2 5 5 1
T3 2 1 7
T4 1 1
Accuracy = 73.3% (33/45)
CRT[+]group 26 4 7 11 10
PET/CT
T0 22 3 2 1
T1 2 1 1 2
T2 4 1 1
T3 1 3
T4 1 4 9
Accuracy = 67.2% (39/58)
CRT chemoradiotherapy, PET/CT positron emission
tomography/computed tomography
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overstaged. PET/CT does not offer detail anatomic in-
formation on how deeply the tumor has grown into the
esophageal wall or into nearby structures. Other alterna-
tives such as PET/MR [32] or EUS if feasible may offer
superior resolution to get more reliably T stage for
esophageal cancer. In patients without luminal obstruc-
tion or patients had no prior CRT before surgery, the T
stage should be determined according to the EUS for in-
creased accuracy [33].
Several studies [25, 34–36] have documented the
value of a PET scan for assessing the esophageal tumor
response to neoadjuvant CRT and for helping to iden-
tify residual disease after CRT. The PET scan, which is
characterized by measuring the FDG concentration in
metabolically active tissue, is independent of morphology
and size despite a persistent mass effect, and offers the
advantage of allowing us to differentiate viable tumors
from tissue with no residual cancer. Using the qualitative
or quantitative imaging analysis of the PET scan, the ac-
curacy of the predictive value compared with the final
pathology examination finding was reported to range
between 53 and 79% [25, 34–36]. In the meta-analysis of
Kwee et al. [37], they recommended that FDG PET should
not yet be used in routine clinical practice to guide neoad-
juvant therapy decisions. This conclusion was made from
twenty heterogeneous groups with heterogeneous ana-
lysis methods. Most of them were composed with both
adenocarcinoma and squamous cell carcinoma. The lar-
gest group with pure squamous cell carcinoma enrolled
32 patients with ESCC [25]. In a subgroup composed of
20 patients, they found the metabolic response measured
by SUVmax changes between pre-CCRT and post-CCRT
FDG PET scans were related to pathologic response with
an accuracy of 70% [25]. Our current study provided a lar-
ger group of patients with ESCC adds to the numerous
studies that have already been performed. In our ROC
analysis, the optimal cut-off SUVmax of 3.4 for a residual
viable tumor was acceptably accurate: 82.8%. Moreover,
an extremely low false-negative rate of 3.1% would be
reached by setting the SUVmax cut-off at 2.2, which is
comparable to the expected mortality rate of an esopha-
gectomy; and an extremely low false-positive rate of 3.9%
would be reached by setting the SUVmax cut-off at 5.5.
These data may help physicians to provide opinions for
patients with different comorbidities or operative risks to
consider suspending or undergoing an esophagectomy
after neoadjuvant CRT.
This study has several limitations. It was retrospective
and thus prone to a selection bias. There was an un-
equal number of patients among each stage. Because of
T4 lesion was not suitable for surgery without pre-
operative CRT in previous clinical practice, there was
only one patient with a T4 lesion in the CRT[−] group.
Moreover, the variance in SUV values of different PET/CT
equipment and the test-retest reproducibility were un-
available from our data. These results should be vali-
dated in a prospective trial of FDG PET/CT for
esophageal cancer.
Conclusions
FDG avidity of a primary esophageal tumor significantly
positively correlated with the pathological T-stage. Al-
though inherently unable to provide sufficient data dir-
ectly distinguish how deeply the tumor has grown into
the esophageal wall, PET/CT with thresholded SUVmax
is useful for predicting the T-stage and for differentiat-
ing residual viable tumors of ESCC, which has the po-
tential helpfulness to select treatment strategies for
patients with esophageal cancer.
Additional file
Additional file 1: Figure S1. One patient in the CRT[−] group with
polypoid esophageal cancer and unexpectedly high fluorodeoxyglucose
(FDG) avidity. Post-surgical histopathology proved the tumor to be stage
T1. Representative (a) coronal (b) sagittal, and (c) transaxial computed
tomography (CT), positron emission tomography (PET), and PET/CT fusion
images (from left to right) showed a focal area of intensely increased
FDG uptake in the lower thoracic esophagus (maximal standardized up-
take value = 9.6); (d) endoscopy showed a polypoid tumor at about the
35 cm level from central incisors; and (e) endoscopic ultrasound showed
the focal mucosal polypoid tumor (14.9 mm × 13.5 mm) invading the
muscularis propria. (PDF 666 kb)
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